CMAJ has been made aware of an error that occurred in the July 31, 2017, issue.1
The second sentence in the first paragraph read, “Tetrahydrocannabinol (THC) and pharmaceutical combinations of THC and cannabidiol (nabiximols) show moderate evidence of benefit for chronic neuropathic and cancer pain.” It should read (change in italics), “Tetrahydrocannabinol (THC) and pharmaceutical combinations of THC and cannabidiol (nabiximols) show moderate evidence of benefit for chronic neuropathic pain.”
The original statement regarding cancer pain is no longer accurate based on recently published phase III studies.
This has been corrected at cmaj.ca.
Reference
- 1.McLeod SA, Lemay J-F. Medical cannabinoids. CMAJ 2017;189:E995. [DOI] [PMC free article] [PubMed] [Google Scholar]